Sun Pharma-Ranbaxy, Holcim-Lafarge deal to face Sebi, CCI scrutiny in India

Subscribe to GoodReturns

Sun Pharma-Ranbaxy, Holcim-Lafarge deal to face Sebi, CCI scrutiny in India
Sun Pharmaceutical- Ranbaxy Laboratories and Holcim-Lafarge deals, which would create pharma and cement behemoths respectively, are likely to face intense regulatory scrutiny in India, especially from Sebi and Competition Commission, reported PTI.

According to the media report, the deals, among the biggest announced so far in 2014, would face intense scrutiny, especially in the context of corporate governance, protecting interests of minority shareholders and overall impact on the competition scenario in the domestic market, sources said.

The Securities and Exchange Board of India (Sebi) would be closely looking at the Sun Pharma-Ranbaxy deal to ensure compliance with stringent norms that are in place for listed entities, said the report.

Besides, the Competition Commission of India (CCI) would have a detailed look at Sun Pharma-Ranbaxy deal as it would create the country's largest pharmaceutical company. CCI is also is expected to have a deeper look at Holcim-Lafarge deal.

Dion Global Solutions Ltd.

Story first published: Wednesday, April 9, 2014, 9:13 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'